. 2016 Oct 20;11(2):124–139. doi: 10.1002/1878-0261.12012

Table 2.

Summary of ITH in each tumor

Patients	Stages	MSI/MSS status	MMR deficiency signature	SNV and microindel mutation details and ITH					Degree of ITH
Patients	Stages	MSI/MSS status	MMR deficiency signature	Overall mutation rate (mut per Mb)	Percentage of heterogenous mutations	Clonal mutations	Subclonal mutations	Evidence of early intermixing	Transcriptomic	Copy number
1	IIIb	MSS	No	4.13	15.4	TP53, FAT4, RAD50, DNMT3A, BRAF	None	No	Low	High
2	IV	MSS	No	9.35	36.7	GLI2, CRTC1, CYB5D2, KRAS, APC, MYH11, APC indel, KAT6A, ACVR1B indel, SOX11	DNMT3A indel^(T), RAF1 indel^(T), EPHA3, TNFRSF14, ADAMTSL3	Yes	High	High
3	IV	MSH2 and MSH6 losses	Yes	56.7	66.7	POLE, KRAS, ACVR2A indel, ERBB2, DNAH1, TP53, RNF43, APC, APC indel, NOTCH1	GATA3, PREX2 indel, FAT1, TGFBR1 indel	No	High	Low
4	I	MSS	No	6.74	48	TP53, TRIO, TIAM1, APC, FAT4, GRM8 indel, SOX9	WHSC1 ^(T) , GRM8 ^(T) , LAMA1, TGFBR2, TIAM1	Yes	Low	Intermediate

Summary of ITH in each tumor at the somatic mutational, transcriptomic, and copy number levels. Heterogeneous mutations refer to nontruncal mutations. Coding mutations that are clonal and subclonal are summarized in this table; ^(T) indicates truncal mutation; see also Figs 2 through 5.